Use of HER2-Directed Therapy in Metastatic Breast Cancer and How Community Physicians Collaborate to Improve Care.
Joanne E MortimerLaura KruperMary CianfroccaSayeh LavasaniSariah LiuNiki Tank-PatelMina S SedrakWade SmithDaphne StewartJames WaismanChristina YeonTina WangYuan YuanPublished in: Journal of clinical medicine (2020)
The development of new HER2-directed therapies has resulted in a significant prolongation of survival for women with metastatic HER2-positive breast cancer. Discoveries in the laboratory inform clinical trials which are the basis for improving the standard of care and are also the backbone for quality improvement. Clinical trials can be completed more rapidly by expanding trial enrollment to community sites. In this article we review some of the challenges in treating metastatic breast cancer with HER2-directed therapies and our strategies for incorporating our community partners into the research network.
Keyphrases
- metastatic breast cancer
- clinical trial
- quality improvement
- healthcare
- positive breast cancer
- mental health
- phase ii
- palliative care
- phase iii
- patient safety
- squamous cell carcinoma
- primary care
- small cell lung cancer
- affordable care act
- study protocol
- stem cells
- health insurance
- randomized controlled trial
- open label
- pain management
- double blind
- hepatitis c virus
- mesenchymal stem cells
- smoking cessation
- chronic pain
- cell therapy
- drug induced
- hiv testing
- human immunodeficiency virus